Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: Arthritis Rheum. 2013 Feb;65(2):513–518. doi: 10.1002/art.37776

Figure 1.

Figure 1

Serial retinal angiograms showing the evolution of peripapillary granulomas in both eyes. Fluorescein angiography reveals severe leakage from the granulomas before treatment, while after treatment the inflammatory leakage is reduced, although residual fluorescein staining in the granulomas is still evident. A and B, Early-phase retinal angiography (at 43 seconds) (A) and late-phase retinal angiography (at 220 seconds) (B) of the right eye, prior to canakinumab treatment. E and F, Early-phase retinal angiography (at 26 seconds) (E) and late-phase retinal angiography (at 231 seconds) (F) of the left eye, prior to canakinumab treatment. C and D, Early-phase retinal angiography (at 38 seconds) (C) and late-phase retinal angiography (at 251 seconds) (D) of the right eye, after canakinumab treatment. G and H, Early-phase retinal angiography (at 48 seconds) (G) and late-phase retinal angiography (at 267 seconds) (H) of the left eye, after canakinumab treatment.